High levels of baseline serum IL-10 are associated with reduced clinical benefit from first-line immune checkpoint inhibitor therapy in advanced renal cell carcinoma

Kim, Youngun; Yang, Hannah; Lee, Won Suk; Cheon, Jaekyung; Sang, Yun Beom; Kang, Beodeul; Chon, Hong Jae; Kim, Chan

doi:10.7150/jca.81384



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2023; 14(6):935-942. doi:10.7150/jca.81384 This issue Cite

Research Paper

High levels of baseline serum IL-10 are associated with reduced clinical benefit from first-line immune checkpoint inhibitor therapy in advanced renal cell carcinoma

Youngun Kim^1*, Hannah Yang^1,2*, Won Suk Lee^1,2, Jaekyung Cheon^1,2, Yun Beom Sang^1,2, Beodeul Kang^1,2, Hong Jae Chon^1,2✉, Chan Kim^1,2✉

1. CHA University School of Medicine, Seongnam, Korea
2. Medical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea
* These authors equally contributed to this work.

✉ Corresponding authors: Chan Kim, M.D., Ph.D. (Lead contact), Associate Professor, Medical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, 59 Yatap-ro, Bundang-gu, Seongnam, 13496, Korea, E-mail: chanac.kr or larrel80com (ORCID: 0000-0001-9780-6155) or Hong Jae Chon, M.D., Ph.D., Associate Professor, Medical Oncology, CHA Bundang Medical Center, CHA University, School of Medicine, 59 Yatap-ro, Bundang-gu, Seongnam, 13496, Korea, E-mail: minidoctorac.kr (ORCID: 0000-0002-6979-5812) More

Citation:

Kim Y, Yang H, Lee WS, Cheon J, Sang YB, Kang B, Chon HJ, Kim C. High levels of baseline serum IL-10 are associated with reduced clinical benefit from first-line immune checkpoint inhibitor therapy in advanced renal cell carcinoma. J Cancer 2023; 14(6):935-942. doi:10.7150/jca.81384. https://www.jcancer.org/v14p0935.htm

Other styles

Abstract

Immune checkpoint inhibitor (ICI) became a standard treatment for advanced renal cell carcinoma (RCC). However, clinically valid biomarkers of therapeutic outcome are lacking. We investigated the role of interleukin-10 (IL-10) as a predictive biomarker for first-line ICI therapy in patients with advanced RCC. Baseline serum samples were prospectively collected and analyzed using a cytometric bead assay. Patients were divided into two groups according to their serum IL-10 levels using maximally selected rank statistics. A fraction (13.0%) of patients had high levels of serum IL-10 at baseline. High serum IL-10 levels (> 4.3 ng/mL) were associated with a significantly shorter progression-free (median: 5.2 months vs. not reached, P = 0.007) and overall survival (median: 13.9 months vs. not reached, P < 0.001). Multivariate Cox regression analysis confirmed the independent association between high serum IL-10 levels and poor survival outcomes. Effector cytokine production and the proliferative response of CD8⁺ T cells were significantly lower in patients with high serum IL-10 levels, who also had a shorter duration of response to first-line ICI therapy (4.6 months vs. not reached, P < 0.001). In conclusion, elevated serum IL-10 levels at baseline were associated with reduced clinical benefit from first-line ICI therapy in patients with advanced RCC.

Keywords: biomarkers, immune checkpoint inhibitor, interleukin-10, advanced renal cell carcinoma, survival

Citation styles

APA

Kim, Y., Yang, H., Lee, W.S., Cheon, J., Sang, Y.B., Kang, B., Chon, H.J., Kim, C. (2023). High levels of baseline serum IL-10 are associated with reduced clinical benefit from first-line immune checkpoint inhibitor therapy in advanced renal cell carcinoma. Journal of Cancer, 14(6), 935-942. https://doi.org/10.7150/jca.81384.

ACS

Kim, Y.; Yang, H.; Lee, W.S.; Cheon, J.; Sang, Y.B.; Kang, B.; Chon, H.J.; Kim, C. High levels of baseline serum IL-10 are associated with reduced clinical benefit from first-line immune checkpoint inhibitor therapy in advanced renal cell carcinoma. J. Cancer 2023, 14 (6), 935-942. DOI: 10.7150/jca.81384.

NLM

CSE

Kim Y, Yang H, Lee WS, Cheon J, Sang YB, Kang B, Chon HJ, Kim C. 2023. High levels of baseline serum IL-10 are associated with reduced clinical benefit from first-line immune checkpoint inhibitor therapy in advanced renal cell carcinoma. J Cancer. 14(6):935-942.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.